Current Edition

COVID-19

US faces ‘critical moment’ in pricing reform that ‘won’t come again,’ nonprofit founder says after tallying 554 new hikes

With 2021 over, the pharmaceutical industry kicked off the New Year with one of its favorite pastimes: raising the prices on hundreds of branded meds. …

Continue Reading →
COVID-19

Pfizer, like Merck, inks deal to license COVID-19 pill and boost global supply

With its highly anticipated COVID-19 oral treatment seemingly on a fast track to approval, Pfizer already is lining it up to be manufactured as a …

Continue Reading →